Remove Cannabinoids Remove Events Remove Patients Remove THC
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo.

article thumbnail

Hemp bill could solve medical patient dilemma

Illinois News Joint

As reported earlier , HB4161 focuses mainly on safety concerns, including permits, licensing, testing, taxes, and a new Hemp Social Equity Fund, but HB4161 also contains amendments that would affect registered Illinois medical cannabis patients and cottage hemp operators as well. To find cannabis-friendly events in Illinois, visit here.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Review: 1:1 THC: CBG and 2:1 THC: CBN gummies by Wyld

Illinois News Joint

While THC may get the most cannabis attention, a ton of really exciting research into many other cannabinoids, such as CBC, CBG and CBN, are coming to light. Wyld is already tapping into some of these cannabinoids and bringing them to consumers through its gummy line. Both come in packages of 10.

THC 86
article thumbnail

FDA Publish Article “5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC”

Cannabis Law Report

More than 100 people in the US have been hospitalized in 2021 after using Delta-8 THC products, federal health regulators warned Tuesday. Delta-8 tetrahydrocannabinol, also known as delta-8 THC, is a psychoactive substance found in the Cannabis sativa plant, of which marijuana and hemp are two varieties. brownies, gummies).

THC 105
article thumbnail

ZYUS Life Sciences Launches New Medical Cannabinoid Formulation for Direct to Patient Sales in Canada

Cannabis Law Report

Launch of Zylem ™ 20:1 further expands ZYUS product offerings with new cannabinoid formulation. The launch of this formulation marks an important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential. About ZYUS Life Sciences Inc. Visit www.zyus.com.

article thumbnail

Study: Potential Adverse Drug Events When Combining THC with Other Medication

The Joint Blog

According to a new study in the Journal of Clinic Medicine , the use of Tetrahydrocannabinol (THC) could have adverse drug effects when combined with other medications due to drug-drug interactions. Its psychoactive ingredient, THC, has made cannabis a highly used recreational drug for millennia. Cannabis Sativa, a.k.a

Events 48
article thumbnail

Study: Cannabinoids Effective for Post Traumatic Stress Patients

The Joint Blog

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS).